Fulcrum Therapeutics, Inc (FULC)

Etorro trading 970x250
Fulcrum Therapeutics, Inc (FULC) Logo

About Fulcrum Therapeutics, Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. Address: 26 Landsdowne Street, Cambridge, MA, United States, 02139

Fulcrum Therapeutics, Inc News and around…

Latest news about Fulcrum Therapeutics, Inc (FULC) common stock and company :

Can Fulcrum Therapeutics, Inc. (FULC) Climb 31% to Reach the Level Wall Street Analysts Expect?
14 Oct, 2021 Yahoo! Finance

The consensus price target hints at a 30.9% upside potential for Fulcrum Therapeutics, Inc. (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Analysts Expect PTH Will Reach $181
07 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $180.51 per unit.

Fulcrum Therapeutics's Return On Capital Employed Overview
22 Sep, 2021 FinancialContent

Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q2 sales of $4.38 million. Earnings fell to a loss of $19.68 million, ...

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Shares Of Fulcrum Therapeutics Inc. Rise Above Previous 52-Week High
21 Sep, 2021 Yahoo! Finance

Shares of Fulcrum Therapeutics Inc. (NASDAQ: FULC) traded today at $33.00, eclipsing its 52-week high. Approximately 12.2 million shares have changed hands today, as compared to an average 30-day volume of 7 million shares. Fulcrum Therapeutics Inc. share prices have moved between a 52-week high of $33.00 and a 52-week low of $6.85 and are now trading 367% above that low price at $32.00 per share. Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It has developed a proprie

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society
20 Sep, 2021 FinancialContent
Cramer Weighs In On Lennar, Alibaba And More
15 Sep, 2021 FinancialContent

On CNBC's "Mad Money Lightning Round," Jim Cramer said he needs something less speculative than Original BARK Co (NYSE: ...

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10 Sep, 2021 FinancialContent
Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer
08 Sep, 2021 FinancialContent
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
02 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences
02 Sep, 2021 FinancialContent
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
01 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
27 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
26 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
24 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Highs On Monday
23 Aug, 2021 FinancialContent

Before 10 a.m. ET on Monday, 119 companies hit new 52-week highs. Noteables: The largest company by market ...

2 Soaring Biotech Stocks With More Fuel in the Tank
23 Aug, 2021 FinancialContent

These recent winners still have a long way to run.

Insider Bets Paying Off At FULC As New 52-Week High Reached
18 Aug, 2021 FinancialContent

In trading on Wednesday, shares of Fulcrum Therapeutics Inc (FULC) touched a new 52-week high of $26.89/share. That's a 292.55% rise, or $20.04 per share from the 52-week low of $6.85 set back on 07/27/2021..

10 Biggest Price Target Changes For Tuesday
17 Aug, 2021 FinancialContent

Citigroup cut the price target on Wix.com Ltd. (NYSE: WIX) from $320 to $250. Wix.com shares fell 1.6% to close at $202.16 on ...

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
16 Aug, 2021 FinancialContent
Is Fulcrum Stock a Buy Right Now? This Is What You Need to Know
16 Aug, 2021 Yahoo! Finance

To say the phase 1 results of FTX-6058, Fulcrum Therapeutics’ (FULC) potential treatment for sickle cell disease (SCD) excited investors would be a serious understatement. Shares took off by over 180% last week as the drug displayed signs it could be beneficial for those suffering from SCD, a rare disease and one with a high unmet medical need. The candidate is based on Fulcrum’s proprietary FulcrumSeek technology, a pioneering method for the discovery of new drugs. In the early-stage testing, h

News Flash: Analysts Just Made An Incredible Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
16 Aug, 2021 Yahoo! Finance

Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders will have a reason to smile today, with the analysts making...

The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
15 Aug, 2021 FinancialContent

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among those that reported during the week.

The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
15 Aug, 2021 FinancialContent

Biopharma stocks retreated in the week endingAug. 13, defying the optimism that was found in the broader market. Earnings ...

Fulcrum Therapeutics Reaches Analyst Target Price
13 Aug, 2021 FinancialContent

In recent trading, shares of Fulcrum Therapeutics Inc (FULC) have crossed above the average analyst 12-month target price of $20.83, changing hands for $22.45/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..

Analyzing Fulcrum Therapeutics's Unusual Options Activity
12 Aug, 2021 FinancialContent

On Thursday, shares of Fulcrum Therapeutics (NASDAQ:FULC) saw unusual options activity. After the option alert, the stock price moved ...

Mid-Afternoon Market Update: Dow Drops 50 Points; IEC Electronics Shares Spike Higher
12 Aug, 2021 FinancialContent

Toward the end of trading Thursday, the Dow traded down 0.14% to 35,435.25 while the NASDAQ rose 0.29% to 14,808.42. The S&P also ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

66 Biggest Movers From Yesterday
12 Aug, 2021 FinancialContent

Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last ...

Fulcrum Therapeutics, Inc (FULC) is a NASDAQ Common Stock listed in , ,

970x250